Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors.

Background & Introduction: The advent of the sodium-glucose cotransporter-2 inhibitors [SGLT-2i] provides an additional tool to combat diabetes and complications. The use of SGLT-2i leads to effective and durable glycemic control with important reductions in body weight/fat and blood pressure. These agents may delay beta-cell deterioration and improve tissue insulin sensitivity, which might slow the progression of the disease. Methods & Results: In response to glycosuria, a compensatory rise in endogenous glucose production, sustained by a decrease in plasma insulin with an increase in glucagon has been described. Other possible mediators have been implicated and preliminary findings suggest that a sympathoadrenal discharge and/or rapid elevation in circulating substrates (i.e., fatty acids) or some yet unidentified humoral factors may have a role in a renal-hepatic inter-organ relationship. A possible contribution of enhanced renal gluconeogenesis to glucose entry into the systemic circulation has not yet been ruled out. Additionally, tissue glucose utilization decreases, whereas adipose tissue lipolysis is stimulated and, there is a switch to lipid oxidation with the formation of ketone bodies; the risk for keto-acidosis may limit the use of SGLT-2i. These metabolic adaptations are part of a counter-regulatory response to avoid hypoglycemia and, as a result, limit the SGLT-2i therapeutic efficacy. Recent trials revealed important cardiovascular [CV] beneficial effects of SGLT-2i drugs when used in T2DM patients with CV disease. Although the underlying mechanisms are not fully understood, there appears to be "class effect". Changes in hemodynamics and electrolyte/body fluid distribution are likely involved, but there is no evidence for anti-atherosclerotic effects. Conclusion: It is anticipated that, by providing durable diabetes control and reducing CV morbidity and mortality, the SGLT-2i class of drugs is destined to become a priority choice in diabetes management.

[1]  R. DeFronzo,et al.  Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes , 2017, Diabetes.

[2]  Huilin Tang,et al.  SGLT2 inhibitor plus DPP‐4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta‐analysis , 2018, Diabetes, obesity & metabolism.

[3]  Michael Heung,et al.  PATHOPHYSIOLOGY AND MANAGEMENT OF HYPOGLYCEMIAIN END-STAGE RENAL DISEASE PATIENTS: A REVIEW. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[4]  M. Hediger,et al.  The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression. , 1994, The Journal of biological chemistry.

[5]  H. Krebs,et al.  RENAL GLUCONEOGENESIS. IV. GLUCONEOGENESIS FROM SUBSTRATE COMBINATIONS. , 1963, Acta biologica et medica Germanica.

[6]  K. Khunti,et al.  Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study , 2017 .

[7]  R. DeFronzo,et al.  Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes , 2013, Diabetes Care.

[8]  M. Tsuda,et al.  Na+‐Glucose Cotransporter (SGLT) Inhibitors as Antidiabetic Agents. Part 4. Synthesis and Pharmacological Properties of 4′‐Dehydroxyphlorizin Derivatives Substituted on the B Ring. , 2000 .

[9]  H. Parker,et al.  Na+-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion , 2011, Diabetes.

[10]  D. Gopinath,et al.  Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives , 2016, Indian journal of endocrinology and metabolism.

[11]  V. Vallon,et al.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition , 2017, Diabetologia.

[12]  P. Felig,et al.  Liver and kidney metabolism during prolonged starvation. , 1969, The Journal of clinical investigation.

[13]  P. Garlick,et al.  Insulin regulation of renal glucose metabolism in humans. , 1999, The American journal of physiology.

[14]  D. Boulton,et al.  Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects , 2009, Clinical pharmacology and therapeutics.

[15]  H. Koepsell,et al.  SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. , 2014, American journal of physiology. Renal physiology.

[16]  E. Ferrannini,et al.  CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis , 2016, Diabetes Care.

[17]  E. Ravussin,et al.  Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men. , 2016, The American journal of clinical nutrition.

[18]  A. Scheen Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus , 2014, Drugs.

[19]  A. Eid,et al.  Intrinsic gluconeogenesis is enhanced in renal proximal tubules of Zucker diabetic fatty rats. , 2006, Journal of the American Society of Nephrology : JASN.

[20]  J. Wahren,et al.  Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting. , 1999, Diabetes.

[21]  M. Hediger,et al.  The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. , 1994, The Journal of clinical investigation.

[22]  C. Bailey,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.

[23]  R. DeFronzo,et al.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition , 2017, Nature Reviews Nephrology.

[24]  W. Guder,et al.  Enzyme distribution along the nephron. , 1984, Kidney international.

[25]  Xiuli Zhang,et al.  Common Drugs for Stabilization of Renal Function in the Progression of Diabetic Nephropathy and Their Relations with Hypertension Therapy. , 2017, Current diabetes reviews.

[26]  Chari D Smith,et al.  Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. , 2005, Diabetes.

[27]  R. Ghosh,et al.  SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus , 2012, Journal of clinical pharmacology.

[28]  C. Pollock,et al.  Glucose handling by the kidney. , 2011, Kidney international. Supplement.

[29]  R. DeFronzo,et al.  Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. , 1987, The Journal of clinical investigation.

[30]  R. DeFronzo,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[31]  D. Kipnis,et al.  Hormone-fuel interrelationships during fasting. , 1966, The Journal of clinical investigation.

[32]  U. Broedl,et al.  Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.

[33]  J. Kullberg,et al.  Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. , 2012, The Journal of clinical endocrinology and metabolism.

[34]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[35]  J. Gerich Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[36]  William C Stanley,et al.  Myocardial substrate metabolism in the normal and failing heart. , 2005, Physiological reviews.

[37]  I. Hirsch,et al.  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.

[38]  S. Del Prato,et al.  Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin , 2011, Diabetes Care.

[39]  E. Ferrannini,et al.  Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.

[40]  V. Vallon The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. , 2015, Annual review of medicine.

[41]  P. Garlick,et al.  Abnormal glucose handling by the kidney in response to hypoglycemia in type 1 diabetes. , 2001, Diabetes.

[42]  É. Hardy,et al.  Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. , 2016, The lancet. Diabetes & endocrinology.

[43]  G F Cahill,et al.  Starvation in man. , 1970, The New England journal of medicine.

[44]  B. Sacktor,et al.  The Na+ gradient-dependent transport of D-glucose in renal brush border membranes. , 1975, The Journal of biological chemistry.

[45]  C. Maack,et al.  Cardiac effects of SGLT2 inhibitors: the sodium hypothesis , 2018, Cardiovascular research.

[46]  C. Mathieu,et al.  Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes , 2015, Diabetes Care.

[47]  K. Kurokawa,et al.  Substrate oxidation by isolated single nephron segments of the rat. , 1981, Kidney international.

[48]  H. Yamada,et al.  Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice , 2014, PloS one.

[49]  M. Kipnes Sodium–glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials , 2011 .

[50]  N. Lewis,et al.  Phlorizin: a review , 2005, Diabetes/metabolism research and reviews.

[51]  R. Judd,et al.  Insulin regulation of renal glucose metabolism in conscious dogs. , 1994, The Journal of clinical investigation.

[52]  R. DeFronzo,et al.  SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study , 2016, Diabetes Care.

[53]  J. Aloia,et al.  Total-body sodium and sodium excess. , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  E. Wright,et al.  Renal Na(+)-glucose cotransporters. , 2001, American journal of physiology. Renal physiology.

[55]  M. Stumvoll,et al.  Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. , 1995, The Journal of clinical investigation.

[56]  Ralph A. DeFronzo,et al.  Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans? , 2012, Diabetes.

[57]  A. Scheen Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus , 2014, Clinical Pharmacokinetics.

[58]  P. Garlick,et al.  Insulin regulation of renal glucose metabolism in humans. , 1999, American journal of physiology. Endocrinology and metabolism.

[59]  M. Hediger,et al.  Molecular physiology of sodium-glucose cotransporters. , 1994, Physiological reviews.

[60]  S. Mudaliar,et al.  Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion , 2013, Diabetes Care.

[61]  J. Rosenstock,et al.  Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes , 2012, Diabetes Care.

[62]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[63]  K. Mahaffey,et al.  Clinical Perspective What Is New ? , 2017 .

[64]  R. DeFronzo,et al.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.

[65]  S. Del Prato,et al.  [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]. , 2013, Deutsche medizinische Wochenschrift.

[66]  W. Humphreys,et al.  In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans , 2010, Drug Metabolism and Disposition.

[67]  B. Sacktor Sodium-coupled hexose transport. , 1989, Kidney international.

[68]  T. Heise,et al.  Pharmacological Intervention in Type 2 Diabetes Mellitus - A Pathophysiologically Reasoned Approach? , 2016, Current diabetes reviews.

[69]  C. Mogensen Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. , 1971, Scandinavian journal of clinical and laboratory investigation.

[70]  T. Asano,et al.  T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. , 1999, Diabetes.

[71]  Y. Shechter Insulin-Mimetic Effects of Vanadate: Possible Implications for Future Treatment of Diabetes , 1990, Diabetes.

[72]  N. Abumrad,et al.  Renal lactate metabolism and gluconeogenesis during insulin-induced hypoglycemia. , 1998, Diabetes.

[73]  H. Krebs,et al.  The fuel of respiration of rat kidney cortex. , 1969, The Biochemical journal.

[74]  A. Basu,et al.  Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis? , 2008, Diabetes care.

[75]  P. Lapuerta,et al.  Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes , 2017, The New England journal of medicine.

[76]  T. Heise,et al.  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.

[77]  M. Tsuda,et al.  Na(+)-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives substituted on the B ring. , 1999, Journal of medicinal chemistry.

[78]  M. Jardine,et al.  Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. , 2017, Journal of the American Society of Nephrology : JASN.

[79]  M. Isaji Sodium-glucose cotransporter inhibitors for diabetes. , 2007, Current opinion in investigational drugs.

[80]  R. DeFronzo,et al.  Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. , 1987, The Journal of clinical investigation.

[81]  M. Levine Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials , 2017, Current diabetes reviews.

[82]  D. Earle,et al.  Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. , 1951, The Journal of clinical investigation.

[83]  A. Scheen Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease , 2015, Clinical Pharmacokinetics.

[84]  P. Rothenberg,et al.  Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus , 2013, Journal of clinical pharmacology.

[85]  N. Abumrad,et al.  Renal Glucose Production During Insulin-Induced Hypoglycemia , 1997, Diabetes.

[86]  G. Charpentier,et al.  Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial , 2013, International journal of clinical practice.

[87]  W. Guder,et al.  Renal substrate metabolism. , 1986, Physiological reviews.